Jupiter Endovascular Reports Successful SPIRARE I Study Findings

Jupiter Endovascular, Inc., a medical technology company based in Menlo Park, California, has announced successful results from its first-in-human (FIH) study, known as SPIRARE I. The findings were presented on October 26, 2025, at the Transcatheter Cardiovascular Therapeutics (TCT 2025) conference, highlighting the potential of the company’s proprietary Transforming Fixation (TFX) technology.

The SPIRARE I study is significant as it represents the initial evaluation of this innovative endovascular intervention technology. According to Professor Irene Lang, MD, the Principal Investigator of the study and a Professor of Vascular Biology at the Medical University of Vienna, the results indicate a promising safety profile and efficacy for patients undergoing this new treatment.

In the study, Jupiter Endovascular focused on patients requiring vascular interventions. The data showcased the TFX technology’s ability to provide secure fixation in challenging anatomical scenarios. Over the course of the study, a total of 50 patients were enrolled, and the results demonstrated a 90% success rate in achieving the desired clinical outcomes.

The presentation at TCT 2025 attracted significant attention from cardiovascular specialists and researchers, eager to learn about advancements in endovascular techniques. The initial findings suggest that the TFX technology could enhance the treatment options available for patients with vascular diseases, potentially leading to better health outcomes.

Following the presentation, Professor Lang expressed optimism about the future implications of the study. She stated, “These results are encouraging and suggest that the Transforming Fixation technology may play an important role in advancing endovascular therapies.”

Jupiter Endovascular plans to further investigate the TFX technology through additional studies. The company aims to expand its research and development efforts to refine the technology and explore its applications in various vascular conditions. As the field of endovascular interventions continues to evolve, the findings from the SPIRARE I study contribute valuable insights that may shape future clinical practices.

The TCT 2025 conference provided a platform for leading experts in the field to discuss emerging technologies and innovative approaches to cardiovascular care. Jupiter Endovascular’s presentation underscored the ongoing commitment to enhancing patient care through groundbreaking medical technology.

As the company moves forward, stakeholders are eager to see how the TFX technology will impact the landscape of vascular interventions. With positive early results, Jupiter Endovascular is poised to make significant contributions to the medical community and improve treatment options for patients worldwide.